Health Care and Biotech
Alcidion’s IT Targets Hospital Efficiency
Alcidion is an emerging operator in the field of hospital IT, with technology that can reduce deaths attributable to medical error. The stock price has doubled since it listed on ASX in February this year.
Dec 19 2016
Estia Health Beset By Uncertainty
Estia Health is beset by uncertainty surrounding the sustainability of earnings and this is not expected to moderate in the near term.
Dec 13 2016
Rebound For Sirtex
Michael Gable of Fairmont Equities suggests technically, Sirtex Medical should be set to recover.
Dec 13 2016
Sirtex Reaction Overdone
Increased competition has wedged dose sales for Sirtex Medical but brokers suspect the market’s reaction is overdone.
Dec 12 2016
Previous Stories
Micro Cap Rising Stars – Clover
Jun 25 2009
Food additive company Clover is expanding its horizons.
The Overnight Report: Feeling Better Now
Jun 19 2009
Some positive economic data helped Wall Street to a welcome up-day. Dow up 58. (Locked for subscribers until 10:00 AEST)
CSL To Buy Back Shares, Abandons Talecris Deal
Jun 09 2009
CSL has decided to abandon the blocked Talecris deal and please shareholders with a buyback instead.
Could CSL Still Win Talecris?
Jun 03 2009
According to Southern Cross Equities there is a chance CSL Will still win its battle to acquire Talecris.
CSL Still A Buy, Says Merrills
May 27 2009
BA-Merrill Lynch has caught up to the US rejection of CSL’s proposed acquisition of Talecris.
No Talecris No Reason To Be Negative On CSL
May 26 2009
The company’s proposed Talecris acquisition in the US now appears unlikely to proceed but with solid earnings growth still expected brokers remain positive on the outlook for CSL.
Positive Trends For Oz Private Hospital Players
May 25 2009
A positive trend in private health insurance membership is a good sign for private hospital operators, reports Southern Cross Equities.
Oz Biotechs Up 88% So Far This Year
May 20 2009
Southern Cross Equities analyst Stuart Roberts reports the come back of risk appetite has been good for biotechnology stocks this year.
The Budget And The Stock Market
May 13 2009
There were no real surprises in last night’s budget and no cause for stock market alarm. However specific sectors are winners and losers.
ResMed More Attractive
Apr 14 2009
According to Southern Cross Equities recent share price weakness is increasing the attractiveness of sleep disorder group ResMed.
